One Unifying Technology from Concept to Clinic.
MaxCyte
in one minute.
We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. We understand and scientifically solve partners’ challenges by applying our expertise.
Life Science
for the ExPERT.
Through its Life Sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. We call this line of products our ExPERT platform.
 |
Explore the ExPERT Platform |
Any Cell. Any Molecule. Any Scale.
The ExPERT Family of Flow Electroporation® Instruments
Cell Therapies
with CARMA.
MaxCyte is developing novel CARMA- therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers.
 |
Previously unfeasible
cell-engineering
applications.
Our cell-engineering platform harnesses the power of the cell to accelerate the development of small molecule drugs, biologics, vaccines and cell and gene therapies to address a wide array of acute and chronic disease indications.
|
The MaxCyte Minute.
Learn about cutting-edge applications, new
resources, and upcoming events.
